Summary The combination of irradiation and four agents of clinical interest in the treatment of cervix carcinoma (bleomycin, etoposide, cisplatin and ifosfamide) have been investigated using two human cervix carcinoma xenografts in nude mice. As a model of clinical brachytherapy regimes, radiation was administered at a continuous low dose rate of 5cGymin-1 to a total dose of 9 or 12Gy. No substantial enhancement in tumour growth delay over that observed for radiation alone was observed with bleomycin, etoposide or cisplatin. Ifosfamide, however, led to substantial additional growth delay, an effect which was lost when irradiation was administered at a higher dose rate of 70cGymin-1. As dose-rates of around 5cGymin-1 allow greater repair of radiation damage than at the higher dose-rate without significant cell cycling or repopulation, it is possible that ifosfamide may act as an inhibitor of repair processes in this model. It would be of interest to evaluate the role of ifosfamide and brachytherapy regimes in the clinical treatment of carcinoma of the cervix.
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Carcinoma of the uterine cervix is the third most frequently occurring female gynaecological malignancy. Overall it accounts for 6% of female malignancies. In England and Wales the incidence is 4,400 new cases per year with an overall survival of57% (Cancer Research Campaign, 1986) . With 160,000 deaths per year from all cancers this means that carcinoma of the cervix accounts for 3% of cancer deaths.
Although chemotherapy for metastatic disease does not achieve long-term survival the response rates are relatively high. If chemotherapy were used in a more favourable situation one might hope to improve outcome (Ward et al., 1985) . Thus chemotherapy is being tested in the adjuvant setting along with either surgery or radiotherapy where one of the problems of access of chemotherapy to post-irradiated tissue is eliminated.
The present paper describes the interaction between commonly used chemotherapeutic agents (bleomycin, cisplatin, etoposide and ifosfamide) and low dose-rate irradiation (5cGymin-1) in two recently established carcinoma of the cervix cell lines used in xenograft. These drugs have been used extensively in clinical trials both singly and in combination (Blake et al., 1986; Cohen et al., 1978; Thigpen et al. 1979; Friedlander et al., 1983) . We have chosen to use low dose-rate irradiation at 5cGymin-i on the basis of in vitro studies from this laboratory that have shown doses of 2-5 cGymin-1 allow extensive recovery from radiation damage without significant repopulation or cell cycle progression . In the clinical setting brachytherapy to the cervix is given at approximately 10 Gy to 30 Gy/24 h which is 0.7 cGy min-1 to 2 cGy min-1. In these experiments the low dose-rate of 5cGymin-1 enabled the exposure time to be kept below four hours (total dose 12 Gy), thus minimising stress to the mice.
The aim was to evaluate chemotherapy induced improvement in tumour growth delay in this experimental system while monitoring any increased toxicity of such combined modality treatment using body weight measurements and mortality (Tannock, 1984 (Tannock, , 1986 Table I . There was a maximum SGD of 1.3 for bleomycin and irradiation but this was not significantly different from the SGD for bleomycin or irradiation alone and much less than the SGD noted for HX155. As a consequence of these results the etoposide experiments using HX156 (Figure ld) were performed with a total dose of 12Gy radiation rather than 9Gy but there was little obvious improvement in SGD when drug was combined with irradiation than for irradiation alone.
In the experiments with low dose-rate irradiation and ifosfamide there was substantial additional growth delay with combined treatment (Figure 2a ; Table II ). The SGD for irradiation was 2.3 and for combined irradiation and ifosfamide the SGD was 10. There was only little tumour growth delay for ifosfamide alone.
To further evaluate the effect of combined modality treatment involving ifosfamide, the experiments were repeated using 9Gy total dose irradiation given at a high dose-rate of 70cGymin-1 on a 2000Ci 60Co source. The result is shown in Figure 2b and Table II and demonstrated that high dose-rate irradiation with ifosfamide gave similar SGD as irradiation alone with values of 4-4.3. Toxicity monitoring revealed no additional weight loss in mice when combined treatment was given than with chemotherapy or irradiation alone and no treatment related deaths were observed.
Discussion
In combining radiotherapy and chemotherapy one aims to improve the response rate achieved by either modality alone. The difficulty is to achieve a higher response without unacceptable toxicity, that is, to improve the therapeutic ratio. Four mechanisms have been used to describe the ways in which an improved therapeutic ratio could be achieved. They are, spatial co-operation, independent cell kill, normal tissue protection and enhancement of tumour response (Steel, 1979) .
In the experiments reported here several commonly used chemotherapeutic agents have been used with low dose-rate irradiation (etoposide, cisplatin, bleomycin and ifosfamide). Only ifosfamide and irradiation resulted in a much greater growth delay than irradiation alone. These experiments demonstrated an additive response of low dose-rate irradiation and ifosfamide giving a SGD of 10 with a SGD of 2.3 for irradiation alone in comparison to the high dose-rate irradiation experiments which resulted in an SGD of 4-4.3 for both irradiation and irradiation and ifosfamide.
Using the terminology of Steel this result is called 'enhancement'. This describes a positive interaction where the dose response curve for only one modality is known. In this instance only the dose response for irradiation has been established in the nude mouse. The result of combined treatment was marked tumour growth delay where either modality alone did not achieve a substantial effect. When ifosfamide was given with high dose-rate irradiation the tumour growth delay achieved by the combination of drug and irradiation was no different to that achieved by irradiation alone. In addition the growth delay for high dose-rate irradiation, with or without Ifosfamide, was less than the growth delay for the combination of low-dose rate irradiation and drug by a factor of four. This suggests that the mechanism by which ifosfamide acts with low dose-rate irradiation, might involve inhibition of the repair that would normally be seen with low dose-rate irradiation given alone. The concept of the loss of low dose-rate sparing has been reported from this laboratory previously when lung tolerance was investigated using irradiation and cyclophosphamide (Lockhart et al., 1986 ) and the potential for lung damage when irradiation is combined with cyclophosphamide in bone marrow transplantation is well documented (Barrett et al., 1983) . As far as we are aware this is the first report of increased tumour growth delay with chemotherapy and low dose-rate irradiation in a human tumour model. More data, particularly in vitro using tumour cell lines, are needed to evaluate the mechanism of this interaction. Ifosfamide is an alkylating agent which causes cell death largely as a result of its ability to form cross-links in DNA, although it also acts by substitution reactions, base alkylation and phosphate group esterification. Radiation is known to cause base damage, single and double stranded DNA breaks and DNA-DNA and DNA-protein cross-links (Elkind, 1979 for a review). In addition there is some recent evidence (Utsumi et al., 1988) to suggest that, in S-phase cells, radiation-induced sublethal damage may be a cross-linking lesion. It is possible that, during continuous low dose-rate irradiation, ifosfamide could be inhibiting the repair of such a lesion. Further study is required to elucidate the mechanism for the striking enhancement in observed tumour growth delay.
To date there has been a paucity of data to support the use of radiotherapy and chemotherapy concurrently in solid tumours as patient survival is rarely improved and greater toxicity usually results (Tannock, 1984; 1986) . However in some squamous cell tumours such as carcinoma of the anal canal there have been encouraging reports of improved local control with combined treatment using 5-Fluorouracil (5-Fu) (Cummings et al., 1984; Meeker et al., 1986) .
In patients with carcinoma of the cervix where low dose-rate irradiation is used as intra-cavitary treatment in early stage disease there is potential benefit, for those patients with a high risk of recurrence, to use ifosfamide concurrently with irradiation if normal tissue tolerance and systemic toxicity are acceptable. Clinical testing is required to determine if this approach produces improved local and/or systemic tumour control and/or survival.
